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Background
Criteria for good candidate antigens for immunotherapy of acute myeloid leukemia are high
expression on leukemic stem cells in the majority of patients with acute myeloid leukemia and
low or no expression in vital tissues. It was shown in vaccination trials that Receptor for
Hyaluronic Acid Mediated Motility (RHAMM/HMMR) generates cellular immune responses in
patients with acute myeloid leukemia and that these responses correlate with clinical benefit.
It is not clear however whether this response actually targets the leukemic stem cell, especially
since it was reported that RHAMM is expressed maximally during the G2/M phase of the cell
cycle. In addition, tumor specificity of RHAMM expression remains relatively unexplored.
Design and Methods
Blood, leukapheresis and bone marrow samples were collected from both acute myeloid
leukemia patients and healthy controls. RHAMM expression was assessed at protein and
mRNA levels on various sorted populations, either fresh or after manipulation.
Results
High levels of RHAMM were expressed by CD34+CD38+ and CD34- acute myeloid leukemia
blasts. However, only baseline expression of RHAMM was measured in CD34+CD38- leukemic
stem cells, and was not different from that in CD34+CD38- hematopoietic stem cells from
healthy controls. RHAMM was significantly up-regulated in CD34+ cells from healthy donors
during in vitro expansion and during in vivo engraftment. Finally, we demonstrated an explicit
increase in the expression level of RHAMM after in vitro activation of T cells.
Conclusions
RHAMM does not fulfill the criteria of an ideal target antigen for immunotherapy of acute
myeloid leukemia. RHAMM expression in leukemic stem cells does not differ significantly
from the expression in hematopoietic stem cells from healthy controls. RHAMM expression in
proliferating CD34+ cells of healthy donors and activated T cells further compromises
RHAMM-specific T-cell-mediated immunotherapy.
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ABSTRACT
Introduction
A priority-ranked list of cancer vaccine target antigens
was published in 2009, ranking the cancer-associated anti-
gens based on predefined and preweighted objective crite-
ria determining the likelihood of their efficacy in cancer
therapy.1 These criteria include therapeutic function in
vaccine trials, immunogenicity, the number of patients
with antigen-positive tumors, expression level, percentage
of positive tumor cells and cellular location, as well as a
role for the antigen in oncogenicity, a tumor-specific
expression profile and expression in cancer stem cells. The
last criterion, the evidence for expression on putative can-
cer stem cells, is likely to be very important in the context
of acute myeloid leukemia (AML). Although 65 to 75% of
patients under 60 years of age with AML reach a complete
hematologic remission through the currently available
standard therapy, the 5-year survival rate is less than 30%,
because a high percentage of the patients relapse.2
Accumulating evidence supports the role of leukemic stem
cells (LSC) in the high relapse rate of AML.2-4 These quies-
cent LSC, possessing biological properties rendering them
resistant to chemotherapy and radiotherapy, are probably
responsible for the minimal residual disease of AML and
may eventually result in relapse. LSC share some proper-
ties with normal hematopoietic stem cells (HSC), such as
a low division rate, self-renewal ability and expression of
some surface markers including the CD34+CD38- pheno-
type.3,4 It is generally believed that sensitive detection of
minimal residual disease and targeted elimination of LSC
can be a very efficient way to achieve more durable remis-
sions or even a cure for AML.3,5 Immunotherapy is expect-
ed to be successful in this setting of minimal residual dis-
ease, complementary to prior standard treatment, by the
elimination of the residual blasts, containing the LSC. 
Receptor for Hyaluronic Acid Mediated Motility
(RHAMM/HMMR/CD168), discovered by the SEREX
(serological screening of cDNA expression libraries)
method, has been described as a cancer-associated antigen
and is involved in both tumorigenesis and progression or
metastasis.6-11 Besides its expression in many solid tumors,
RHAMM mRNA was detected in peripheral blood
mononuclear cells of 60-70% of newly diagnosed AML
patients.6,11 High expression of RHAMM has been correlat-
ed with a poor prognosis in patients with various types of
solid tumors and hematologic malignancies such as B-cell
chronic lymphocytic leukemia, multiple myeloma and
AML.12-16 RHAMM-specific CD8+ T cells were detected in
patients diagnosed with AML and chronic myeloid
leukemia.17-19 Using a lymphoma mouse model, anti-tumor
activity mediated by CD4+ T cells was observed after vac-
cination with RHAMM mRNA-transfected dendritic
cells.20 A recently published report demonstrated pro-
longed survival of immune deficient mice injected with an
AML cell line after adoptive transfer of RHAMM-specific
T-cell receptor (TCR) transgenic lymphocytes.21 In addi-
tion, it was shown in clinical vaccination trials that
RHAMM generates cellular immune responses and,
importantly, clinical responses in some patients with
AML, myelodysplastic syndrome and multiple myelo-
ma.22,23 RHAMM was, therefore, identified as one of the
most promising leukemia-associated antigens in AML. 
It is not clear however whether this RHAMM-specific
response actually targets the true LSC. Expression of
RHAMM in CD34+CD38- LSC has, to the best of our
knowledge, never been specifically investigated. Promising
results have been published concerning CD44, a hyaluro-
nan receptor closely related to RHAMM, which has been
described as a potential target to eliminate AML LSC.3
Another relatively unexplored criterion of leukemia-associ-
ated antigens concerning RHAMM is its tumor specificity.
Greiner et al. showed that RHAMM is not expressed in
peripheral blood mononuclear cells and CD34+ HSC from
healthy volunteers.6,11 However, the specificity of RHAMM
expression was shown to be not absolute, since testis, pla-
centa and thymus showed significant RHAMM mRNA
expression.6,24 Immunohistochemistry of spermatocytes,
normal colonic mucosa and normal gastric mucosa
revealed strong, weak and occasionally positive staining
for RHAMM, respectively.12,16 RHAMM immunostaining
was also demonstrated throughout all layers of the cornea
and suprabasal layers of the limbus.25 Furthermore, it was
reported that RHAMM is differentially expressed during
the cell cycle, with maximal RHAMM mRNA expression
in the G2/M phase.26 As a consequence, RHAMM expres-
sion might be up-regulated in actively dividing cells of
physiological tissues. 
In this study we investigated the expression pattern of
RHAMM in various leukemic and non-leukemic
hematopoietic cell populations that are relevant to
immunotherapy of patients with AML. 
Design and Methods
Samples from healthy volunteers and patients 
with acute myeloid leukemia
All samples were taken from patients with AML treated at
Ghent University Hospital (Belgium) between 2009 and 2011.
Samples were collected at the time of diagnosis or relapse as
indicated in Table 1. AML samples (bone marrow, peripheral
blood or leukapheresis) and cord blood, peripheral blood and
leukapheresis samples (after HSC mobilization) from healthy
donors were obtained and used following the guidelines of the
Medical Ethical Committee of Ghent University Hospital, after
informed consent had been obtained in accordance with the
Declaration of Helsinki. 
Cell lines 
The K562 cell line, a chronic myeloid leukemia-blast crisis-
derived cell line, is often used as a positive control for RHAMM
expression.6,11,17 OP9-GFP is a murine bone marrow stromal cell
line constitutively expressing green fluorescent protein, which can
be flow cytometrically analyzed in the fluorescein isothiocyanate
(FITC) channel. Culture conditions are described in the Online
Supplementary Design and Methods.
Isolation of subpopulations of acute myeloid leukemia
and healthy donor cells
After thawing, CD34+ cells were first enriched by anti-CD34
magnetic activated cell sorting beads (MACS beads, Miltenyi) if
the percentage of CD34+ cells in the sample was <70%.
Subsequently, cells were sorted with the FACSAria II cell sorter
(BD Biosciences) for the viable [assessed by lack of propidium
iodide (Invitrogen) intake] CD34+CD38- and CD34+CD38+ cells to
a purity of >99%, as determined by post-sorting analysis. If the
percentage of CD34+ cells in the sample was >70%, samples were
immediately sorted as described above. CD34- blasts were also
isolated from five AML samples. 
s. snauwaert et al.
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Isolation and  in vitro culture of acute myeloid
leukemia and cord blood samples
The procedures used for the isolation and in vitro culture of AML
and cord blood samples were described by Van de Valle et al.27 and
are detailed in the Online Supplementary Design and Methods. 
T-cell activation 
The T-cell activation is described in the Online Supplementary
Design and Methods.
Flow cytometry and antibodies
Details on the flow cytometry equipment and techniques and
antibodies used are given in the Online Supplementary Design and
Methods.
Cell cycle analysis
Cell cycle analysis is described in the Online Supplementary
Design and Methods. 
In vivo transplantation experiment
Adult NOD.CB17-Prkdcscid/J (NOD/SCID) mice were given a
sublethal dose of whole-body irradiation (3.5 Gy) and injected
intraperitoneally with 200 mg of a rat monoclonal antibody against
the murine IL2-Rβ chain.28 Within 24 h after irradiation, mice were
injected intravenously as described in the Online Supplementary
Design and Methods. 
Real-time quantitative polymerase chain reaction analysis
The techniques, apparatus, kits and primers used for the real-
time quantitative polymerase chain reaction (RT-qPCR) analysis
are described in the Online Supplementary Design and Methods.
RHAMM primers were designed to amplify the four described iso-
forms of RHAMM indifferentially.15 Results were normalized to
GAPDH expression and shown relative to the transcript level in
K562 cells. If pre- and post-proliferation samples were compared,
normalization was performed to the geometric mean of GAPDH,
YWHAZ and R18S expression.29
Statistical analysis
Statistical analysis was performed in SPSS statistics version 19.
The non-parametric related samples Wilcoxon’s signed rank test
and independent samples Mann-Whitney U test were used when
indicated. P values less than 0.05 were considered statistically sig-
nificant.
Results
RHAMM is not expressed in acute myeloid leukemic
stem cells 
CD34+CD38+ AML blasts and CD34+CD38- LSC were
isolated from bone marrow, peripheral blood or leuka-
pheresis samples of 13 AML patients. The clinical,
immunophenotypic and genetic features of the AML
patients cover a range of subtypes of AML and are pre-
sented in Table 1. Samples were taken at diagnosis or
relapse as indicated. Two cord blood samples and two
leukapheresis samples from healthy donors were selected
as controls. Figure 1A shows only background expression
of RHAMM in CD34+CD38- HSC from healthy donors.
This population is considered to be RHAMM-negative.6
No significant difference in RHAMM expression levels
could be demonstrated between the CD34+CD38- and the
CD34+CD38+ subpopulations from healthy donors
(P=0.273). Expression of RHAMM in the CD34+CD38+
AML subpopulation was divergent, with relative expres-
sion levels varying from undetectable to 0.74, calculated
relative to RHAMM expression in K562 cells. RHAMM
expression in CD34- blasts was investigated in five
patients and was not statistically different from the
expression in the CD34+CD38+ blast population (P=0.893).
Strikingly, only baseline RHAMM expression was
observed in the CD34+CD38- LSC, which was not statisti-
cally different from the expression measured in healthy
Table 1. Clinical, immunophenotypic and genetic characteristics of the acute myeloid leukemia patients.
Sample Gender Age De novo/ Cytogenetics CD34  (%) FAB WHO FLT3-ITD NPM1- Source
(years) relapse (karyotype and FISH) mutation mutation
AML1 Female 34 de novo normal 80 M0 AML-NOS with minimal differentiation negative negative bone marrow
AML2 Female 77 de novo normal 30 M2 AML-NOS with maturation negative negative bone marrow
AML3 Male 35 de novo normal 29 M1 AML-NOS without maturation positive negative bone marrow
AML4 Female 63 de novo normal 50 M1 AML-NOS without maturation negative negative bone marrow
AML5 Female 52 de novo normal < 1 M2 AML-NOS with maturation negative negative leukapheresis
AML6 Female 62 de novo normal < 1 M1 AML-NOS without maturation positive positive leukapheresis
AML7 Male 40 de novo inv(16)(p13;q22) 70 M2 AML with inv16 (type D) negative negative leukapheresis
AML8 Female 67 de novo 46XX,inv(7)(q11.2q21) 21 M2 AML-NOS with maturation positive positive leukapheresis
(constitutional)
AML9 Male 54 de novo inv(16)(p13;q22) 57 M2 AML with  inv16 ND ND peripheral blood
AML10 Male 42 de novo 46XY,add(Y)(q12)[6]/ 40 M2 AML-NOS with maturation negative positive bone marrow
46, XY[14](u.s.)
AML11 Male 48 de novo t(15;17)(q22;21) < 1 M3 AML-M3 ND ND bone marrow
AML12 Male 41 de novo t(10;11)(p12;q23) 70 M4 AML with t(10;11), MLL-AF10 negative negative leukapheresis
AML13 Female 24 relapse 47XX,del(7)(q22.q36),+8[12] 71 M2 AML-NOS with maturation negative negative bone marrow
The age of the patients varied between 24 and 77 years.  All AML are primary and cover a range of subtypes of AML according to both the World Health Organization (WHO) classification and the
French-American-British (FAB) classification. CD34 (%) represents the percentage of CD34+ cells in the investigated samples. ND: not determined; NOS: not otherwise specified; u.s.: unknown signifi-
cance; NPM1 mutation: mutation of the nucleophosmin gene at chromosome 5q35;  inv16: inversion 16; MLL-AF10: mixed-lineage leukemia gene at chromosome 11q23 fused with the AF10 transcrip-
tion factor at chromosomal locus 10p12; FLT3-ITD: internal tandem duplication in the fms-like tyrosine kinase-3 gene; FISH: fluorescence in situ hybridization.
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CD34+CD38- HSC (P=0.296). These RT-qPCR data were
confirmed by flow cytometry. Figure 1B shows intracellu-
lar staining for RHAMM expression within the CD34+
AML cells for a representative AML sample (AML12): a
subset of the CD34+CD38+ population clearly expressed
RHAMM, whereas the CD34+CD38- cells were virtually
all negative for RHAMM. This result provides evidence
that, in addition to the differential RHAMM transcript
level, a differential RHAMM protein expression profile
can be seen in the LSC compared with the CD34+CD38+
AML control population.
RHAMM expression in acute myeloid leukemia
is cell cycle-dependent
It was previously shown that RHAMM expression in
human primary fibroblasts is differentially regulated dur-
ing the cell cycle with maximal RHAMM mRNA expres-
sion in the G2/M phase.26 This has been linked to its
important role in mitosis, when RHAMM binds to the
mitotic spindle to regulate spindle integrity and stability.30
We, therefore, hypothesized that, also in AML, RHAMM
expression may not be static during cell cycle progression.
Figure 2 shows cell cycle analysis and RHAMM expres-
sion prior to and after in vitro expansion of AML samples.
Freshly isolated AML cells were mainly in the G0/G1
phase of the cell cycle, while 5 days of in vitro culture
allowed a subpopulation to be pushed towards S phase
(20.1%) and G2/M phase (11.5%) of the cell cycle in this
representative sample (Figure 2A). As hypothesized, in
parallel with this shift in the distribution of the AML cells
in the different phases of the cell cycle, an approximately
8-fold increase in RHAMM mRNA expression was
observed after 5 days of in vitro culture of two representa-
tive AML samples (Figure 2B). These RT-qPCR results
were confirmed by flow cytometry showing a clear up-
regulation of RHAMM protein expression after culture in
the bulk of AML cells (Figure 2C). Interestingly, after 5
days of culture, although most cells had differentiated to
CD34- cells, a small but distinct CD34+CD38- LSC subpop-
ulation was sustained, in which RHAMM protein expres-
sion remained undetectable (Figure 2D).
In vitro expansion of cord blood-derived CD34+ cells
causes up-regulation of RHAMM 
Taking into account that the RHAMM protein and
mRNA levels increased upon in vitro expansion in AML
cells, we investigated whether this was also the case for
non-malignant (both CD38+ and CD38-) CD34+ HSC. To
explore the RHAMM expression profile of expanding
HSC, human cord blood-derived CD34+ cells from five dif-
ferent donors were analyzed prior to and after in vitro cul-
ture. RT-qPCR showed a significant up-regulation of
RHAMM mRNA in the expanded CD34+ cells compared
with in freshly isolated CD34+ cells (Figure 3A). The
expression levels in expanding healthy CD34+ cells were
of comparable magnitude as those in AML samples under
expansion conditions. These results suggest that not only
malignant AML cells, but also CD34+ cells from healthy
donors show cell cycle-dependent changes in the level of
RHAMM mRNA. In addition to higher RHAMM mRNA
expression, a strong up-regulation of cytoplasmic
RHAMM protein levels was observed in the CD34+ cells
after expansion (Figure 3B). This result could be linked
again to the distribution of the cells in the different phases
s. snauwaert et al.
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Figure 1. RHAMM expression profile in LSC versus HSC (A) From 13 AML samples and four samples from healthy donors two subpopulations
were isolated by FACS sorting: CD34+CD38- LSC and the CD34+CD38+ control population from AML patients, and the CD34+CD38- HSC and
CD34+CD38+ subpopulation from healthy donor samples. From five AML patients the CD34- blast population was isolated too. The box plot
shows RHAMM expression levels measured by RT-qPCR on mRNA. Results were normalized to GAPDH expression and shown relative to the
RHAMM transcript level in K562 cells. The o symbol represents an outlier, with a relative expression of RHAMM of 0.74. There is no
significant difference in RHAMM expression level between the CD34+CD38- HSC samples and the CD34+CD38+ healthy subpopulation
(P=0.273 calculated by Wilcoxon’s test). Supplementary analysis showed no significant difference in RHAMM expression between the CD34-
and the CD34+CD38+ AML blasts for five investigated samples (P=0.893 calculated by Wilcoxon’s test). The CD34+CD38- LSC samples had
a significantly lower RHAMM expression level compared with the CD34+CD38+ AML control population (P=0.001 calculated by Wilcoxon’s
test). No statistically significant difference could be shown between the LSC and the HSC (P=0.296 calculated by the Mann Whitney U test).
(B) Intracellular staining for RHAMM on a representative AML sample (AML12). Plots are gated on the viable cells and show the further
gating strategy. Gated on the CD34+ AML cells (left dot plot), the right dot plot shows that intracellular RHAMM expression can be mainly
found in the CD34+CD38+ subpopulation. Gated on isotype control (not shown).
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of the cell cycle prior to and after in vitro expansion, as
shown in Figure 3C. Cell cycle analysis of a representative
sample shows that freshly isolated CD34+ cells were virtu-
ally all in the G0/G1 phase, in contrast to the distribution
of cells after expansion when a subpopulation shifted
towards the S phase (29.3%) and G2/M phase (7.3%) of
the cell cycle.  
Cord blood-derived CD34+ cells up-regulate RHAMM
during engraftment in a NOD/SCID mouse model
A NOD.CB17-Prkdcscid/J (NOD/SCID) mouse model
was used to address the question whether the up-regula-
tion of RHAMM observed in vitro during expansion of cord
blood-derived CD34+ cells can be observed in vivo too and,
therefore, whether it is clinically relevant. Two weeks
after injection of cord blood-derived CD34+ cells, mice
were sacrificed and bone marrow was collected.
Engrafting hCD45+ hCD34+ mCD45- cells made up in
average 1.88% (representative sample shown: 5.79%) of
the total viable bone marrow cells and were sorted to high
purity (Figure 4A). RHAMM expression in the CD34+ cells
prior to injection and after 2 weeks of engraftment was
determined by RT-qPCR. As shown earlier, RHAMM
expression level was very low in freshly isolated healthy
CD34+ cord blood samples (Figure 4B). Two weeks after
transplantation, a significant up-regulation in RHAMM
expression (P=0.012) was seen in the CD34+ human cord
blood-derived cells: there was a mean 75.3-fold increase
after 2 weeks. RHAMM primers were tested on whole
mouse bone marrow of a non-injected mouse, and no
RHAMM expression could be observed, indicating the
specificity of the human RHAMM primers (data not
shown). Because the monoclonal antibody against
RHAMM is non-conjugated, it was technically not feasible
to confirm these RT-qPCR results flow cytometrically,
combining intracellular RHAMM staining with surface
staining of all required markers. In conclusion, these data
suggest that, also in vivo, RHAMM is clearly expressed on
the engrafting non-malignant CD34+ cells in the bone mar-
row during the expansion phase after HSC transplanta-
tion.
In vitro activated T cells over-express RHAMM
Immunotherapeutic strategies are based on two major
principles. On the one hand, cytotoxic T cells can be isolat-
ed from the patient and selected or genetically engineered
to express a TCR of interest to be subsequently expanded
in vitro and re-transfused to the patient. On the other hand,
cytotoxic T cells can be activated in vivo by vaccination
with peptides, DNA or dendritic cells.22,23,31 In both cases
activated cytotoxic T cells are indispensable in order to
obtain immunological and clinical responses in the AML
patient. As we observed up-regulation of RHAMM in
cycling CD34+ cells from healthy donors, we also studied
the change in RHAMM expression upon T-cell activation.
No RHAMM mRNA expression could be detected in fresh
peripheral blood mononuclear cells, freshly isolated
TCRαβ+ T cells and freshly isolated CD8+ TCRαβ+ cytotox-
ic T cells (Figure 5A), in accordance with previous
reports.6,24 Upon activation, a clear increase in RHAMM
mRNA levels was observed. This up-regulation was con-
firmed by intracellular flow cytometric analysis (Figure 5B).
Taken together, these data indicate that in vitro activation
induces RHAMM expression in cytotoxic CD8+ T cells.
RHAMM in immunotherapy of AML
haematologica | 2012; 97(10) 1543
Figure 2. RHAMM expression
before and after in vitro culture of
AML cells. (A) Cell cycle analysis
of a representative bulk AML
sample (AML8) before (day 0) and
after in vitro culture (day 5).
Freshly isolated AML samples are
mainly in the G0/G1 phase.
Dean/Jett/Fox analysis after 5
days of in vitro culture shows 67%
of cells in the G0/G1 phase,
20.1% in the S phase and 11.5%
in the G2/M phase. (B) RT-qPCR
analysis on mRNA is shown for
the expression of RHAMM in
freshly isolated bulk AML sam-
ples (day 0) and in AML samples
after 5 days of in vitro culture (day
5). Results were normalized to
the geometric mean of the
expression of GAPDH, R18S and
YWHAZ, and are shown relative to
the RHAMM transcript level in
K562 cells. Data shown are the
mean values and standard devia-
tions (SD) calculated from dupli-
cate PCR of the same sample.
Results are shown for two repre-
sentative AML samples (AML8
and AML12). 
(C) Histogram demonstrating flow cytometric results of intracellular RHAMM expression on day 0 and day 5 after in vitro culture of a represen-
tative bulk AML sample (AML8). Compared with isotype staining (day 0 = day 5) (solid gray) and expression on day 0 (full line), clear up-regulation
can be seen after 5 days of culture (dotted line). (D) Dot plots are gated on the viable cells and show the further gating strategy. Gated on the
CD34+ AML cells (AML8; left dot plot), the right dot plot shows intracellular RHAMM expression after 5 days of in vitro culture. The expression in
the CD34+CD38- subpopulation remains low, compared with that in the CD34+CD38+ population. Gated on isotype control (not shown).
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Discussion
Herein, we show that the expression of RHAMM, a can-
cer-associated antigen currently explored as a target for
immunotherapy and especially for vaccination trials, is
low to undetectable in the CD34+CD38- LSC of AML
patients and not significantly different from that in the
CD34+CD38- HSC of healthy donors. These results are in
accordance with the putative role assigned earlier to
RHAMM as a negative marker of the stem cell-containing
population of human limbal epithelial cells. Ahmad et al.
located RHAMM in all layers of corneal epithelium and
suprabasal layers of the limbal epithelium. In contrast,
RHAMM was completely absent in the basal layer of the
limbus where the stem cells are located.25 In view of the
fact that the beneficial effects of immunotherapeutic
strategies for AML are expected to be mainly situated in
targeting minimal residual disease after prior standard
therapy, targeting the chemoresistant LSC is essential for a
durable effect. However, the data presented here suggest
that RHAMM-directed immunotherapeutic strategies will
not target LSC but only the rapidly proliferating progeny.
Such therapies may, therefore, offer little added value to
standard therapy (e.g. poly-chemotherapy). Of course, we
cannot exclude that the background level of RHAMM
mRNA, detected in LSC, may be sufficient for recognition
by high-avidity T cells. Still, the conclusion remains that,
as RHAMM mRNA expression levels in HSC and LSC are
not significantly different, both LSC and HSC may be
attacked similarly by RHAMM-directed high-avidity T-
cell-based therapies.
We observed that RHAMM expression in AML blasts is
not static but cell cycle-dependent, in accordance with a
previous study indicating that RHAMM is not constitu-
tively expressed by all AML blasts, but only by a subpop-
ulation.13 These findings are in line with those of earlier
studies demonstrating that RHAMM expression in human
primary fibroblasts and the HeLa cell line varies during cell
cycle, as low expression was measured in G0/G1 cells and
a peak in mRNA level was observed during the G2/M
phase.26,32 This expression pattern can be related to the
intracellular function of RHAMM: it decorates the mitotic
spindles and seems to be necessary for stable mitotic spin-
dle formation and progression through the G2/M
phase.7,26,30,33-35 In addition, other studies demonstrated a
direct or indirect correlation between RHAMM and prolif-
eration, both in malignant cells and in physiological non-
homeostatic settings such as wound healing and regener-
ation.14,32,35-38 It is not, therefore, surprising that in a variety
of hematologic and solid malignancies, RHAMM over-
expression was described to be correlated with a poor
prognosis.12-16 We strongly believe that this correlation is
not only due to the function of RHAMM in cell motility
and, consequently, the invasiveness of tumor cells,30 but
can also be attributed to RHAMM being a genuine ‘prolif-
eration marker’. The major drawback of the proliferation-
dependent expression of RHAMM is that non-malignant,
actively dividing cells tend to express high levels of
RHAMM too. 
We confirm previous findings that freshly isolated
CD34+ HSC from healthy donors do not express RHAMM
mRNA.6,11 However, we observed a clear up-regulation of
RHAMM after in vitro expansion of CD34+ HSC from
healthy donors. These findings were confirmed in vivo dur-
ing the process of CD34+ cell expansion in a mouse model
of human stem cell transplantation. For ethical and practi-
cal reasons, we were unable to study CD34+ cells during
the engraftment phase after HSC transplantation in
patients. However, we and others have shown that
human CD34+ cells transplanted into irradiated immune-
deficient mice engraft in the bone marrow and expand
dramatically during the first weeks after infusion.28 As this
s. snauwaert et al.
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Figure 3. RHAMM expression in human cord blood-
derived CD34+ cells before and after in vitro expan-
sion (A) Box plot showing RHAMM mRNA expression
in freshly isolated CD34+ cells (day 0) and in CD34+
cells after 7 days of in vitro culture (day 7) from five
different cord blood donors. RHAMM expression was
measured by RT-qPCR on mRNA and results were
normalized to the geometric mean of the expression
of GAPDH, R18S and YWHAZ and shown relative to
the RHAMM transcript level in K562 cells. There is a
significant difference in RHAMM expression level
between day 0 and day 7 (P= 0.043 calculated by
Wilcoxon’s test). (B) Histogram showing flow cyto-
metric results of intracellular RHAMM expression on
day 0 and after 7 days of in vitro culture of CD34+
cells. Gated on the viable CD34+ GFP- cells.
Compared with isotype staining (day 0 = day7) (solid
gray) and with RHAMM expression on day 0 (full
line), clear up-regulation can be seen after 7 days of
culture (dotted line). Results shown are representa-
tive of three distinct cord blood donors analyzed. (C)
Cell cycle analysis of a representative CD34+ cord
blood sample before (day 0) and after in vitro culture
(day 7). Freshly isolated CD34+ cells are virtually all
in the G0/G1 phase. Dean/Jett/Fox analysis after 7
days of in vitro culture showed 63% of cells in the
G0/G1 phase, 29.3% in the S phase and 7.3% in the
G2/M phase. 
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mouse model mimics in vivo engraftment of autologous
(post-chemotherapy) or donor (allogeneic HSC transplan-
tation) HSC, our data suggest a major limitation for
immunotherapy targeting RHAMM: RHAMM-specific
cytotoxic T cells might not be able to discriminate engraft-
ing non-leukemic HSC from leukemic cells and might,
therefore, hamper post-chemotherapy recovery or
engraftment of allogeneic HSC in the context of allogeneic
HSC transplantation. A recent study showed a reduction
of colony-forming units of all lineages when freshly isolat-
ed HLA-A2+ CD34+ HSC from healthy donors were co-
incubated with TCR-transgenic lymphocytes specific for
RHAMM in the context of HLA-A2, suggesting that fresh-
ly isolated CD34+ cells may express enough RHAMM to
be killed by these T cells.21 However, it is more likely that
CD34+ HSC up-regulated RHAMM expression in response
to the growth factors added during the assay.
Alternatively, since an allo-HLA-A2-restricted RHAMM-
specific TCR was used, it is also possible that CD34+ cells
were killed due to off-target promiscuity.39 Although, until
today, no major toxicity has been reported in RHAMM
vaccination trials,22,23 more potent immunotherapeutic
strategies such as adoptive transfer of RHAMM-specific T
cells might induce important hematologic and non-hema-
tologic side effects.  
We not only found RHAMM expression in HSC during
hematologic recovery but also in cytotoxic T cells prolifer-
ating upon immune activation. Our results are consistent
with those of Leisegang et al.,40 who showed that survivin-
specific T cells underwent fratricide when activated,
because of the target antigen, survivin, being also
expressed in activated T cells. In a recently published
paper by the same group on RHAMM-specific T cells, this
issue was not addressed in depth as it was not reported
whether HLA-A2 negative or positive effector T cells were
used for treatment and whether differential T-cell toxicity
was observed.21 Nevertheless, our data suggest that cellu-
lar therapy targeting RHAMM might be limited by in vivo
fratricide of the RHAMM-specific T cells activated by the
AML cells, and by collateral damage to neighboring acti-
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Figure 4. RHAMM expression
before and after transplanta-
tion of human cord blood-
derived CD34+ cells in
NOD/SCID mice. Eight adult
NOD/SCID mice were intra-
venously injected with 2.5x105
cord blood-derived CD34+
cells. (A) Plots are gated on
the viable cells, and show the
sorting strategy. Dot plots illus-
trate a representative mouse 2
weeks after transplantation of
hCD34+ cord blood-derived
cells. The percentage of
hCD45+ mCD45- hCD34+ cells
within the viable bone marrow cells is 5.79%. (B) Box plot showing the results of RT-qPCR analysis for RHAMM mRNA in freshly isolated
CD34+ cells (pre-injection= pre) and in CD34+ cells isolated from the bone marrow 2 weeks after intravenous injection (post). Results were
normalized to the geometric mean of the expression of GAPDH, R18S and YWHAZ, and are shown relative to the RHAMM transcript level in
K562 cells. There is a significant difference in RHAMM expression level between the ‘pre’ and ‘post’ samples (P=0.012 calculated by
Wilcoxon’s test), with firm up-regulation of RHAMM mRNA 2 weeks after transplantation. 
Figure 5. RHAMM expression by in vitro activated T cells (A) RT-qPCR on mRNA from T-cell subpopulations (peripheral blood) from two dif-
ferent healthy donors. Bulk peripheral blood mononuclear cells (PBMC) were analyzed prior to and 1 and 5 days after in vitro activation by
phytohaemagglutinin (PHA). From the same donors the CD3+TCRαβ+ and the CD3+TCRαβ+CD8+ fractions were sorted and analyzed unstim-
ulated, on day 1 and on day 5 of CD3/CD28/CD49d activation. The results were normalized to the geometric mean of the expression of
GAPDH, R18S and YWHAZ, and are shown relative to the expression level in K562 cells. Data shown are the mean values and SD calculated
from two donors. (B) Histograms demonstrating flow cytometric results of intracellular RHAMM expression on day 0 and 5 days after in vitro
activation by PHA of a representative bulk PBMC sample (left) and gated on the CD8+ T cell subpopulation (right). Compared with isotype
staining (day 0 = day 5; solid gray) and expression on day 0 (full line), clear up-regulation can be seen after 5 days of stimulation (dotted
line). 
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vated T cells with unknown specificity. Similarly, vaccina-
tion strategies able to induce autologous RHAMM-specific
T cells could be of limited efficacy because of apoptosis of
the responding cytotoxic T cells. 
Although RHAMM is a well-known and abundant can-
cer-associated antigen, over-expressed in several hemato-
logic and solid malignancies, our data raise the question
whether it should be used at all as a target for
immunotherapy. We have not directly addressed whether
certain splice variants may be uniquely associated with
AML or malignancy in general. It is known that some
truncated isoforms of the RHAMM protein have trans-
forming properties when over-expressed in cell lines.33 In
multiple myeloma, over-expression of mRNA of a splice
variant without exon 4 was seen.15 If these truncated pro-
tein forms result in unique newly composed peptides
specifically expressed in malignant cells, and one of those
peptides binds with a high affinity to a major histocom-
patibility complex (MHC) class I allotype, new
immunotherapeutic strategies could emerge that are more
specific and, therefore, potentially safer and more effi-
cient. However, our RT-qPCR results, using primers that
were designed to amplify all four isoforms of RHAMM
described until now, showed no expression in the LSC,
which excludes expression of known alternatively spliced
mRNA isoforms. The dual function of RHAMM, involving
both an extracellular and intracellular localization, makes
it more complicated to address the RHAMM protein
expression level. Extracellular expression of RHAMM
results from a redistribution of intracellular pools by non-
conventional export to the extracellular compartment,
which is not necessarily associated with increased synthe-
sis or improved stability of RHAMM mRNA or protein.30
Surface staining of AML cells with an anti-RHAMM
mono clonal antibody could not demonstrate clear extra-
cellular RHAMM expression on AML blasts in our hands
(data not shown), in accordance with the predominant intra-
cellular localization of RHAMM in AML blasts described
earlier in immunohistochemical stainings.13 Furthermore,
it is expected that epitopes processed from intracellular
RHAMM by the target cells and presented on MHC class
I complexes will be by far the most important targets for
recognition by cytotoxic T cells.
In conclusion, we have evaluated RHAMM as an
immunotherapeutic target in the context of AML, guided
by the internationally accepted criteria for prioritization of
cancer-associated antigens.1 The expression in LSC is low
to undetectable and RHAMM is not AML-specific, since it
is also expressed in expanding healthy HSC and activated
T cells, two clinically relevant populations in the context
of a future integrated AML treatment, consisting of the
standard induction chemotherapy followed by
immunotherapy as a consolidation treatment or an allo-
geneic HSC transplant followed by AML-directed donor
lymphocyte infusions. In brief, the two major benefits of
immunotherapy over chemotherapy, the elimination of
LSC and the reduction of side effects, are not likely to be
achieved by RHAMM-directed immunotherapy. 
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